Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Sep 4, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to detect very small amounts of cancer that might remain after treatment for cervical cancer. Researchers are studying a specific type of DNA from the human papillomavirus (HPV) that could help predict if the cancer might come back. By identifying these small traces of cancer, the goal is to create better treatment plans tailored to each patient. The study will follow participants for up to 36 months after their treatment ends.

To participate in this trial, women aged 65 to 74 who have been diagnosed with certain types of cervical cancer, specifically stages IA2 to IVA, may be eligible. This includes those who have undergone surgery or a combination of chemotherapy and radiation for their initial treatment. Unfortunately, those who have had another type of cancer in the last three years, are currently pregnant or breastfeeding, or do not wish to sign a consent form cannot join. Participants can expect regular testing and monitoring during the study period to help gather important information about their health and treatment outcomes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pathological diagnosis: cervical squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma
• • FIGO stage: IA2-IVA
• • HPV typing: type 16 or 18
• • ECOG 2-0
• • The initial treatment was surgery (Cohort A) / concurrent chemoradiotherapy (Cohort B)
• Exclusion Criteria:
• • The diagnosis of cervical cancer was made within 3 years of other malignancies
• • Pregnant or lactating women
• • Refused to sign a consent form